

## 

**Citation:** Zhang C, Li X, Brecht M-L, Koniak-Griffin D (2017) Can self-testing increase HIV testing among men who have sex with men: A systematic review and meta-analysis. PLoS ONE 12(11): e0188890. https://doi.org/10.1371/journal. pone.0188890

**Editor:** Dimitrios Paraskevis, National and Kapodistrian University of Athens, GREECE

Received: June 24, 2017

Accepted: October 19, 2017

Published: November 30, 2017

**Copyright:** © 2017 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** This study is funded by Fogarty International Center Award (D43 TW009579) (https://www.fic.nih.gov/Pages/Default.aspx), and partly funded by National Social Science Fund (15CSH037) (http://www.npopss-cn.gov.cn/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. RESEARCH ARTICLE

# Can self-testing increase HIV testing among men who have sex with men: A systematic review and meta-analysis

#### Ci Zhang<sup>1</sup>, Xianhong Li<sup>1</sup>\*, Mary-Lynn Brecht<sup>2</sup>, Deborah Koniak-Griffin<sup>2</sup>

1 Xiangya Nursing School of Central South University, Changsha, Hunan, China, 2 UCLA School of Nursing, Los Angeles, California, United States of America

\* xianhong\_li228@hotmail.com

## Abstract

### Background

Globally, four out of ten individuals living with HIV have not been tested for HIV. Testing is especially important for men who have sex with men (MSM), among whom an increasing HIV epidemic has been identified in many regions of the world. As a supplement to site-based HIV testing services, HIV self-testing (HIVST) provides a promising approach to promote HIV testing. However, evidence is scattered and not well-summarized on the effect of HIVST to improve HIV testing behaviors, especially for MSM.

#### Methods

Seven databases (PubMed, Web of Science, Cochrane Library, PsycINFO, CINAHL Plus, WanFang, and China National Knowledge Internet) and conference abstracts from six HIV/ sexually transmitted infections conferences were searched from January 2000-April 2017.

### Results

Of 1,694 records retrieved, 23 studies were identified, 9 conducted in resource-limited countries and 14 in high-income countries. The pooled results showed that HIVST increased HIV test frequency for MSM by one additional test in a 6-month period (mean difference = 0.88 [95% CI 0.52–1.24]). The pooled proportion of first-time testers among those who took HIVST was 18.7% (95% CI: 9.9–32.4) globally, with a rate 3.32 times higher in resource-limited country settings (32.9% [95% CI: 21.3–47.6]) than in high-income countries (9.9% [95% CI: 7.4–13.8]). The pooled proportions included non-recent testers, 32.9% (95% CI: 28.1–38.3); ever or currently married MSM, 16.7% (95% CI: 14.5–19.4); and HIV positive men, 3.8% (95% CI: 2.0–5.7) globally; 6.5% [95% CI: 0.38–12.3] in resource-limited country settings; and 2.9% [95% CI: 2.0–5.0] in high-income countries). The rates reported for linkage to care ranged from 31.3% to 100%.

### Conclusions

HIVST could increase HIV testing frequency and potentially have capacity equivalent to that of site-based HIV testing services to reach first-time, delayed, married, and HIV-infected



**Competing interests:** The authors have declared that no competing interests exist.

testers among MSM and link them to medical care. However, more rigorous study designs are needed to explore the specific self-testing approach (oral-fluid based or finger-prick based) on improving HIV testing for MSM in different social and economic settings.

#### Introduction

Globally, approximately 36.7 million individuals are living with HIV, with about 2.2 million new cases identified annually over the past 5 years [1-4]. Notably, men who have sex with men (MSM) account for 30% of all HIV infected people in the world [3], and 49% of the cases in MSM are reported in Western Europe, Central Europe, and North America [3]. The HIV epidemic is rapidly growing among MSM in some regions of the world, especially in China with 29.4% of new infections occurring among MSM [5]. However, an estimated 4 in 10 of HIV positive individuals, globally, have not been tested for HIV [4]. A recent meta-analysis synthesizing studies from China showed that about half of Chinese MSM had never been tested for HIV in their lifetime, and 62% had not been tested in the past 12 months [6]. Inadequate uptake of HIV testing, high frequency of unprotected sexual behaviors, and multiple sexual partners may potentially fuel the HIV epidemic among the MSM population, and may also bridge the epidemic to the general population through heterosexual contact with women, especially in developing and undeveloped countries [7,8]. Late testing and late access to treatment also remain a main cause of HIV/AIDS-related deaths[9]. Therefore, improving HIV testing becomes the first and key step to achieve, by 2020, the "90-90-90" goal set up by UNAIDS in 2014 (90% of people with HIV get tested and diagnosed, 90% of those diagnosed get treatment, and 90% of individuals on treatment get virally suppressed)[10].

HIV self-testing (HIVST) provides a promising approach to expand HIV testing. HIVST is defined as an approach in which individuals collect their own specimens and then conduct a test and read the results by themselves [11], thus, the dried blood spot (DBS) self-collection approach is excluded, because the test is not performed and the result is not read by the client themselves. There are two types of self- testing: one is oral-fluid based testing kits, and the other is finger- prick based kits. Currently only one oral HIV self-test kit is commercially available which was approved by the U.S. Food and Drug Administration (FDA) in 2012 (Ora Quick In-Home HIV Test). In most countries, oral self-testing kits are much more expensive than finger-prick self-testing kits [11]. The characteristics of more privacy, convenience, and confidentiality of HIVST were expected to facilitate increasing HIV testing, especially for MSM [12-14], but in reality, not as many MSM as predicted have used HIVST. For example, although HIVST kits are widely available and accessible in China, only 6.1% to 26.2% of MSM have ever used HIVST [15-17]. The barriers may include perceived unreliable results, no perception of HIV risk, concerns about correct HIVST operation, relatively high cost, fear of positive results, and concerns about lack of support if a test were positive [18]. Some experts have also worried about potential psychological risks and difficulty in linking positive individuals to treatment [19,20].

WHO (2016) recently released a new guideline on HIV self-testing and partner notification, with the recommendation to support trained lay providers to deliver HIVST using rapid diagnostic tests (RDTs) and emphasis on the need for strategic approaches to deliver the kits [11]. However, evidence is scattered and not well-summarized on the effect of HIVST to improve HIV testing for the specific group of MSM. This systematic review was conducted to address the knowledge gap by synthesizing the evidence on (1) whether HIVST could increase the HIV test frequency for MSM; (2) the capacity of HIVST to reach first-time testers among MSM; (3) the capacity of HIVST to reach non-recent testers; (4) the capacity of HIVST to reach the hidden subgroup of married MSM (with women); (5) the capacity of HIVST to identify more HIV-positive men; and (6) the linkage-to-care rate for HIV-positive men identified by HIVST (because of concerns that individuals using HIVST without supervision might fail to seek care following a positive result)[21].

#### Methods

#### Inclusion criteria

We conducted a systematic literature review to evaluate the current evidence on the effectiveness of HIVST to promote HIV testing among MSM. The target population was defined as MSM who reported ever taking HIVST. Studies were eligible if they reported data on at least one of the following outcomes: (1) the frequency of HIV testing; (2) the proportion of firsttime testers; (3) the proportion of non-recent testers; (4) the proportion of ever or currently married MSM; (5) the proportion of people who had HIV positive results; (6) the proportion of linkage- to-care for those who had positive results through HIVST. The specific definitions of the six outcome variables are described in <u>Table 1</u>. Randomized controlled trials (RCTs), quasi-experimental studies, and observational (cross-sectional, case-control, and cohort) studies were eligible for inclusion in this meta-analysis. The intervention in RCT and quasi-experimental studies was restricted to HIVST only. Baseline data were used to conduct the metaanalysis for the above outcomes if the study was not observational. The study was excluded if it was not an original investigation, duplicated results from another study, or was qualitative.

This review was reported following PRISMA guidelines[22].

#### Search strategy

We searched 7 electronic databases (PubMed, Web of Science, Cochrane Library, PsycINFO, CINAHL Plus, WanFang, and the China National Knowledge Internet) and conference abstracts from International AIDS Society (IAS), International Congress of Behavioral Medicine (ICBM), Infectious Diseases Society of America (IDSA), Canadian Association of HIV Research (CAHR), HIV Diagnostics Conference (HDC) and International Society for Sexually Transmitted Diseases Research (ISSRTDR) for publications from January 2000 to April 2017. Our search terms (limited to humans) included (HIV OR HIV seropositivity OR HIV infection) AND ((self test\*) OR (home\*test\*) OR (rapid\*test\*)) AND ((men who have sex with men) OR MSM OR homosexuality OR gay OR bisexual\*)), using MeSH terms for PubMed and comparable terms for other databases. The search was limited to English-language and

Table 1.	<b>Definitions of</b>	the outcome	variables
----------	-----------------------	-------------	-----------

Outcome variables	Definition
Frequency of HIV testing	The number of HIV tests that MSM took in the past 6 months (including all kinds of testing approaches)
First-time testers	Individuals who self-report having taken an HIV test for the first time
Non-recent testers	Individuals who self-report not having taken an HIV test in the past year
Ever or currently married MSM	MSM who were ever or are currently married to women
HIV-positive MSM	MSM who demonstrate HIV-positive results by using self-testing approaches
Linkage to care	MSM who demonstrate HIV-positive results using a self-testing approach, seek confirmatory testing in clinic/hospital/CDC, and get enrolled in a medical care or treatment program



Fig 1. Flow chart of selection procedure and outcomes of this systematic review.

Chinese-language articles. There were no geographic limitations. Abstracts were included if full texts were not available. We screened gray literature through Google Scholar. Additionally, bibliographies of relevant papers were manually searched and the authors contacted for original data when needed. The details were listed in the flow chart (Fig 1).

#### Data screening and extraction

Two reviewers (C.Z. and X.L.) independently screened titles and abstracts of the articles referring to MSM and HIVST. And then, full text and abstracts were screened for all eligibility criteria. Discrepancies (about 6%) were resolved by discussion after reviewing the full text. A standard data extraction form was used to extract variables from identified studies (Table 2).

#### Quality assessment

The methodological quality of the included studies was assessed using JBI-MAStARI standard appraisal tools[23] (S1 Doc), including tools for randomized controlled trials (S1 Table), cross-sectional studies (S2 Table), and quasi-experimental studies (S3 Table). A mixed-method

2017         Automatications         Conductors         Conductors <thconductors< th="">         Conductors         Conductor</thconductors<>		Author Year	Setting	Design	Sample Size	Product Kit	HIV Testing Frequency	The First Time Testers (%)	Non- recent Testers (%)	Married MSM(%)	HIV(+) Person (%)	Linkage to Care (%)	Score for Quality Critique (%)
5         Seate.USA         FOT         Intervention: microality conditionation (SS) conditionationationationationationationation	Jamil 20 <sup>-</sup>	2	Australia	Waiting- list RCT	Intervention:178; control:165	Oral-fluid	Intervention: mean 4.0 per year (95% CI: 3.7–4.3); control: mean 1.9 per year (95% CI: 1.7–2.2) RR 1.9 (95% CI:1.7– 2.2)	NA	16.9% (30/178)	NA	1.7% (3/ 178)	100% (3/3)	100% (13/ 13)
14         Los Angeles         Ce         So         Orellud         Mode         Sev. (1)         No.         Sev. (26)         No.         Sev. (27)         No.         Sev. (27)         No.         Sev. (27)         No.         Sev. (27)         No.         N	(atz 201	ى ک	Seattle, USA	RCT	Intervention:115; control:115	Oral-fluid	Intervention: mean 5.3per15month(95% CI: 4.7,6.0); control: mean 3.6 per 15 month (95% CI: 3.2,4.0)	NA	AN	ν	NA	NA	46% (6/13)
1         Chan         Cs         341         Engerprick         74/25/-34         74/26/-34         74/26/-34         74/26/-34         74/26/-34         74/26/-34         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36         74/26/-36	Marlin 20	014	Los Angeles, USA	QE	50	Oral-fluid	NA	NA	30% (15/ 50)	NA	6% (3/50)	100% (3/3)	67% (6/9)
016         058-Anglesis         0E         122         07-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)         153-8-(13)	Qin 201		China	S	341	Finger-prick 242/341 (71%); Oral-fluid 99/ 341 (29%)	79 (23%, 341) reported HIV test frequency increased after first using HIVST	58.7% (200/341)	59% (117/ 143)	18% (117/647)	11.7% (40/341)	78% (31 /40)	100% (8/8)
Variant, ChinaCE200CrathuldCurahuldMu $10^{10}$ $22^{10}$ , $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$ $20^{10}$	Huang 2	016	Los Angeles, USA	QE	122	Oral-fluid	NA	10.7% (13/ 122)	39% (47/ 122)	NA	1.6% (2/ 122)	100% (2/2)	67% (6/9)
015         Hong Kong         CS         66         Figesynick         NA         NA         NA         44% (3)         100% (3)         100% (3)           10112         France         CS         69         NA         NA         29% (1)         59% (3)         100% (3)         100% (3)           10112         France         CS         69         NA         NA         29% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3)         100% (3) <td< td=""><td>j 2016</td><td></td><td>Yunnan, China</td><td>QE</td><td>200</td><td>Oral-fluid</td><td>NA</td><td>NA</td><td>NA</td><td>21.5% (43/200)</td><td>23% (46/ 200)</td><td>NA</td><td>67% (6/9)</td></td<>	j 2016		Yunnan, China	QE	200	Oral-fluid	NA	NA	NA	21.5% (43/200)	23% (46/ 200)	NA	67% (6/9)
1212         Fance         CS         68         NA         NA         12.2% (1V)         56% (4)         56% (4)         56% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)         66% (4)	Nong 2	015	Hong Kong	CS	68	Finger-prick (76.5%)	NA	NA	NA	NA	4.4% (3/ 68)	100% (3/3)	100% (8/8)
016         LangZhou, China         CE         198         NA         NA         278%(56, 66)(196         45%(6/ 66)(196         45%(6/ 776)         45%(6/ 778)         45%(6/ 778)         65%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68)         56%(68) <td>Greace</td> <td>n 2012</td> <td>France</td> <td>cs</td> <td>69</td> <td>NA</td> <td>NA</td> <td>12.2% (10/ 82)</td> <td>50% (41/ 82)</td> <td>NA</td> <td>2.9% (2/ 69)</td> <td>66.7% (2/ 3)</td> <td>100% (8/8)</td>	Greace	n 2012	France	cs	69	NA	NA	12.2% (10/ 82)	50% (41/ 82)	NA	2.9% (2/ 69)	66.7% (2/ 3)	100% (8/8)
4         Beijng, China         CE         Fingerprick         NM         50.9%         NM         20%, 40%         15%, 33         00%, 33         66%, 46%           5         Jangsu, China         CS         Tage prick         NM         733, 10         NM         20%, 40%         15%, 63%         60%, 63%         66%, 65%         63%         63%         63%         63%         65%         63%         63%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%         65%	Zhong 2	016	Guang Zhou, China	QE	198	NA	NA	27.8% (55/ 198)	45.5% (65/198)	8.1% (16/ 178)	4.5% (8/ 178)	100% (8/8)	56% (5/9)
5         Jangau China         CS         137         Fingerprick18 huld 17 (13.39%)         NA         177 %         NA         N	Fao 201	4	Beijing, China	QE	220	Finger-prick	NA	50.9% (112/220)	NA	20% (40/ 200)	15% (33/ 220)	100% (33/ 33)	56% (5/9)
17         London, UK         GE         Se86         Oral-fluid or Finger-prick         NA         NA         NA         15% (93)         88% (82')         67% (61')           2016         San Francisco, USA         GE         53         Oral-fluid or Finger-prick         NA         NA         15% (93)         89% (82')         85% (82')         85% (82')         85% (82')         85% (82')         85% (82')         85% (82')         85% (82')         85% (82')         85% (82')         85% (82')         85% (82')         85% (82')         85% (82')         85% (82')         85% (82')         85% (82')         85% (82')         85% (82')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')         85% (81')	ran 20 <sup>-</sup>	D	Jiangsu, China	cs	137	Finger-prick118 (86.1%);Oral- fluid 17 (13.9%)	NA	7.3% (10/ 137)	NA	17.5% (24/137)	NA	NA	100%(8/8)
2016         San Francisco, USA         CE         53         Coral-fluid         NA         208%         NA         10% (5/         80% (45)         56% (5/           115         Beijng, China         QE         384         Oral-fluid         NA         NA         NA         NA         0.5% (2)         1:3% (5/         56% (5/)           115         Beijng, China         QE         384         Oral-fluid         NA         NA         NA         NA         0.5% (2)         1:3% (5/)         56% (5/)           116         America         QE         1071         Oral-fluid         NA         NA         NA         0.9% (11')         67% (3')         56% (5/)           2016         United         CS         2409         Oral-fluid         NA         9.5% (20)         412%         NA         83% (7)           2016         Kingdom         CS         2409         Oral-fluid         NA         9.5% (20)         412% (7)         NA         83% (7)           2016         Kingdom         CS         2409         Oral-fluid         NA         NA         NA         83% (7)         NA         83% (7)           2016         Usagewise         QE         35% (9)         NA </td <td>Elliot 20</td> <td>17</td> <td>London, UK</td> <td>QE</td> <td>5696</td> <td>Oral-fluid or Finger-prick</td> <td>NA</td> <td>NA</td> <td>AN</td> <td>NA</td> <td>1.6% (93/ 5696)</td> <td>88% (82/ 93)</td> <td>67% (6/9)</td>	Elliot 20	17	London, UK	QE	5696	Oral-fluid or Finger-prick	NA	NA	AN	NA	1.6% (93/ 5696)	88% (82/ 93)	67% (6/9)
15Beijng, China $CE$ $384$ $Oral-fluidNaNaNaNa0.5^{*} (2^{\prime}1.3^{\circ} (5^{\prime}56^{\circ} (5^{\prime}16AmericaCE10710ral-fluidNa58^{*} (62^{\prime}385^{\circ}Na0.5^{*} (11^{\prime}100^{\circ} (11^{\circ}100^{\circ} (11^{\circ}100^{\circ} (11^{\circ}100^{\circ} (11^{\circ}100^{\circ}$	Noods	2016	San Francisco, USA	QE	53	Oral-fluid	NA	NA	20.8% (11/53)	NA	10% (5/ 53)	80% (4/5)	56% (5/9)
16         America         CE         1071         5.8% (62/         38.5%         NA         0.9% (11/         100% (11/         67% (61/           2016         United         CS         2409         Cal-fluid         NA         95% (23)         11671)         1071)         1071)         1071)         67% (61/         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67% (61//         67%	Zhou 20	115	Beijing, China	QE	384	Oral-fluid	NA	NA	NA	NA	0.5% (2/ 384)	1.3% (5/ 16)	56% (5/9)
2016         United         Cs         2409         Oral-fluid         NA         3.8%         NA         88% (7)           2016         Kingdom         Cs         37         NA         9.5% (20)         41.6%         NA         3.8%         NA         88% (7)           2016         Los Angeles,         CE         37         NA         NA         NA         134/         88% (7)           2017         Edinbugh, and Dundee, UK         MM         999         Oral-fluid         NA         NA         NA         4% (1/37)         NA         67% (8)           15017         Edinbugh, and Dundee, UK         MM         999         Oral-fluid         NA         15.4%         NA         8% (1)         NA         8% (7)           15010         Edinbugh, and Dundee, UK         MM         999         Oral-fluid         NA         15.4%         NA         8% (7)           15010         Los Angeles,         De         12.4%99         NA         8.8% (1)         NA         8.8% (7)           15010         Los Angeles,         DE         1255         NA         8.8% (1)         NA         4.8% (2)         00% (2)         00% (2)	arov 20	16	America	QE	1071	Oral-fluid	NA	5.8% (62/ 1071)	38.5% (412/ 1071)	NA	0.9% (11/ 1268)	100% (11/ 11)	67% (6/9)
2016         Los Angeles, USA         GE         37         NA         NA         NA         NA         4% (1/37)         NA         67% (6/ 67% (6/ Na           2017         Glaspow, Dundee, UK         MM         999         Oral-fluid         NA         15.4%         NA         4% (1/37)         NA         67% (6/ 67% (6/ 1151)         MA         67% (6/ 67% (6/ 75% (6/ 75% (1/15)         MA         88% (7)           ren2016         Los Angeles, USA         QE         125         Oral-fluid         NA         8.8% (1/1         37.6%         NA         4% (2/56)         100% (2/2)         67% (6/ 67% (6/ 67% (6/ 67% (6/	<b>McDaid</b>	2016	United Kingdom	cs	2409	Oral-fluid	NA	9.5% (230 /2409)	41.6% (1001/ 2409)	AN	3.8% (134/ 3549)	AN	88% (7/8
2017         Glasgow, Edinburgh, and Dundee, UK         MM         999         Oral-fluid         NA         15.4%         NA         5.3% (61/         NA         88% (7)           ren2016         Los Angeles, USA         QE         125         Oral-fluid         NA         8.8% (11/         37.6%         NA         4% (2/56)         100% (2/2)         67% (6)	Daniels	2016	Los Angeles, USA	QE	37	NA	NA	NA	NA	NA	4% (1/37)	NA	67% (6/9)
ren2016 Los Angeles, QE 125 Oral-fluid NA 8.8% (11/ 37.6% NA 4% (2/56) 100% (2/2) 67% (6) USA	lowers	2017	Glasgow, Edinburgh, and Dundee, UK	WW	666	Oral-fluid	NA	15.4% (154/999)	NA	AN	5.3% (61/ 1151)	NA	88% (7/8)
	Joseng	ren2016	Los Angeles, USA	QE	125	Oral-fluid	NA	8.8% (11/ 125)	37.6% (47/125)	NA	4% (2/56)	100% (2/2)	67% (6/9)

Table 2. Characteristics of included studies.

(Continued)	
Table 2. (	

	ithor Year	Setting	Design	Sample Size	Product Kit	HIV Testing Frequency	The First Time Testers (%)	Non- recent Testers (%)	Married MSM(%)	HIV(+) Person (%)	Linkage to Care (%)	Score for Quality Critique (%)
20 Carb Die <sup>/</sup> g	allo- iuez 2012	New York City, USA	QE	44	Oral-fluid	NA	AN	NA	NA	6.8% (3/ 44)	NA	67% (6/9)
21 Volk	2016	Peru and Brazil	QE	103	Finger-prick	NA	15.5% (16 /103)	44.7% (46/103)	14.6% (15/103)	1.9% (2/ 103)	100% (2/2)	67% (6/9)
22 Han;	2014	China	S	1342	NA	NA	54.6% (434/795)	30.7% (245/797)	15.5% (206/ 1342)	6.1% (49/ 805)	AN	100% (8/8)
23 Chav	/ez 2016	USA	QE	511	Oral-fluid and finger-prick	AN	NA	NA	NA	2.2% (11/ 511)	NA	67%(6/9)

NA, not available; CS, cross-sectional; OE, quasi-experimental; MM, mixed method (a survey and expert focus groups)

designed study [24] was evaluated using the cross-sectional study checklist of JBI-MAStARI, as data were only extracted from the cross-sectional phase. A conference abstract [25] was evaluated using the Randomized Controlled Trials of the JBI-MAStARI appraisal checklist. After assessment of the quality by the two independent reviewers, disagreements were resolved through discussion. The risk of bias was evaluated according to Agency for Healthcare Research and Quality (AHRQ) methods[26] (S4 Table).

#### Statistical analysis

Review Manager 5.3 was used to summarize the results. A meta-analysis was conducted on the efficacy of HIVST on improving HIV test frequency. Mean difference (MD) was applied as summary measures, with 95% confidence intervals (95% CI) reported. Mean Difference was calculated for HIV test frequency. If the pooled MD was higher than 0, it indicates an increase in the test frequency in the HIV self-testing group as compared to the standard-of-care group.

For the remaining meta-analyses of single proportion, the incidence rate P and the value of standard error were calculated with formulas: P = ln(x/(n-x)) and  $SE(P) = (1/x+1/(n-x))^{1/2}$ , respectively. In the two formulas, x indicated the number of events, and n indicated the total number of objects observed. Odds ratio (OR) was calculated using the software of Review Manager 5.3, with 95% CI reported. The pooled percentage and 95% CI were calculated using formulas:  $P_t = OR/(1+OR)$ , the lower limit of 95% CI: LL = LLOR/(1+LLOR) and the upper limit of 95% CI: UL = ULOR/(1+ULOR). In the three formulas,  $P_t$  indicated the pooled proportion, LLOR indicated the lower limit of OR, and ULOR indicated the upper limit of OR.

I-squared ( $I^2$ ) values were used to assess the impact of study heterogeneity. According to the Cochrane review guidelines, if  $I^2$  was less than 50%, the inverse variance fixed-effects model was chosen; otherwise, the DerSimonian-Laird random-effects model was used when clinical heterogeneity was big. If the number of included studies was more than 10, a funnel plot was conducted to assess publication bias [27,28]. For consistency, all figures were labeled "exp (HIVST)" vs "control (standard care)," even when studies were not strictly experimental.

#### Results

A total of 1694 records were retrieved, 1661 from database searching, 26 from conference abstracts, and 7 from bibliography search. After duplicates were removed, 1321 records were identified. Records (n = 1088) were excluded if review of the title or abstract revealed that the topic was unrelated to HIV self-testing. The eligibility of the remaining 232 records was assessed by reviewing full-text articles (if available), and finally 23 studies were selected (21 full-text studies and 2 abstracts). Reasons for exclusion of the 209 studies are elaborated in Fig 1.

The 23 eligible studies were conducted from 2009 to 2015 and results published from 2012 to 2017 (including 4 in 2017, 9 in 2016, and 5 in 2015). Twenty-one studies were published in English and two in Chinese. Geographically, ten studies were conducted in the USA, eight in China, three in the United Kingdom, one in France, and one in Peru and Brazil. In other words, nine studies (39.1%, n = 9/23) were conducted in resource-constrained country settings [15,17,21,29–34] and 14 (60.9%, n = 14/23) in high-income countries [16,24,25,35–45]. The total sample size varied from 37 to 5696. The minimum age of participants in selected studies was 16 years old. An oral fluid-based test was the main testing method in the majority of studies (56.5%, n = 13/23), while a finger-prick based test alone was reported only in two studies; five studies reported using both testing methods, and four did not specify the product kits (Table 2). Only two studies were randomized controlled trials [25,35]; the majority were quasi-experimental (60.9%, n = 14/23) [21,30–34,36,38–40,42–45], while six were surveys (26.1%,

n = 6/23 [15-17,29,37,41], and one was a mixed methods design (4.5%, n = 1/22) (survey and expert focus group) [23].

Reported outcome variables included frequency of HIV testing (3 studies), and the proportion of first time testers (12 studies), non-recent testers (12 studies), married MSM (7 studies), people who had HIV positive tests (21 studies), and linkage to care (14 studies) (Table 2). The quality of each study is evaluated below in detail in S2–S4 Tables. The quality appraisal scores were 100% in six studies (26.1%, n = 6/23) [29–31,35,36], 88% in two studies (8.7%, n = 2/23) [16,37], 67% in nine studies (43.5%, n = 10/23) [15,17,24,32,34,38,40,43–45], 56% in four studies (17.4%, n = 4/23) [33,39,41,42] and 46% in one study (4.3%, n = 1/23) [25] (S1–S3 Tables).

#### The efficacy of HIVST to increase HIV test frequency

Only two RCT studies evaluated the efficacy of HIVST to improve HIV test frequency among MSM. One was carried out in Australia [35], and the other was in the USA [25]. The pooled study results indicated that MSM who were provided with HIVST kits as a supplement to sitebased testing services had nearly one more test in a 6-month period than those who were provided with only site-based testing services (mean difference = 0.88; 95% CI 0.52, 1.24) (see Fig 2). In China, a nationwide online survey showed that 23% (n = 77/341) of those who ever took HIVST self-reported increasing HIV test frequency either by HIVST or site-based testing after first time using self-test kits[29].

In addition, the study in Australia also analyzed the testing frequency for delayed testers (those who had not been tested in the last 2 years or had never been tested before), and the results showed that MSM provided with HIVST as a supplementary option had 3.95 times higher test frequency than those men provided with only standard of care (Rate Ratio = 3.95; 95% CI 2.30, 6.78, P<0.0001)[35].

# The proportion of first time testers, non-recent testers, ever or currently married MSM and HIV positive MSM

The included studies, pooled proportions and ranges, ratios of the proportion in resource-limited countries/the proportion for all included studies for the four outcome variable of first time testers, non-recent testers, ever or currently married MSM and HIV positive MSM were listed in Table 3.

The pooled proportion of the first time testers among those taking HIVST was 18.7% (95% CI: 9.9–32.4%) for the 12 included studies (Fig 3). The pooled estimated proportion of first-time testers was 9.9% (95% CI: 7.4–13.8%) in high-income countries (Fig 4), and 32.9% (95% CI: 21.3–47.6%) (Fig 5) in resource-limited countries, which was 3.32 times higher than the percentage for high-income countries and 1.76 times higher than the total combined percentage.

The proportion of non-recent testers accounting for MSM who ever took HIVST varied from 15.7% (n = 57/362) in Australia [35] to 59% (n = 117/143) in China [29]. The pooled

	F	IIVST		standa	ard of c	are		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV. Random, 95% CI
Jamil 2017	2	1.02	178	0.95	0.82	165	55.2%	1.05 [0.85, 1.25]	
Katz 2015	2.12	1.31	98	1.44	0.81	99	44.8%	0.68 [0.38, 0.98]	
Total (95% CI)			276			264	100.0%	0.88 [0.52, 1.24]	•
Heterogeneity: Tau <sup>2</sup> =	0.05; Cł	ni² = 4.	02, df =	= 1 (P = (	0.04); l²	= 75%		-	-4 -2 0 2 4
Test for overall effect:	Z = 4.81	(P < (	0.00001	1)					Favours [experimental] Favours [control]

Fig 2. Meta-analysis on mean number of HIV tests for MSM in a 6-month period.



Outcomes	The included	d studies (n, ref.No)		The p	ooled propo	rtion	Range	Ratio
	AIS	HIC	RLC	AIS	HIC	RLC		
First-time testers	<b>12</b> [15,17,21,24,29,30,32,34,37,40,41,43]	6(50%, n = 6/12) [24,30,37,40,41,43]	6 (50%, n = 6/12) [15,17,21,29,32,34]	18.7%(95% Cl: 9.9– 32.4%) (Fig 3)	9.9% (95% Cl: 7.4– 13.8%) (Fig 4)	32.9% (95% Cl: 21.3– 47.6%) (Fig 5)	From 5.8%, (n = 62/1071) [40] to 58.7%, (n = 200/341) [29]	RLC/HIC: 3.32 RLC/ AIS: 1.76
Non-recent testers	<b>12</b> [15,21,25,30,34–37,39,41,43]	8 (66.7%, n = 8/12) [30,35-37,39-41,43]	4 (33.3%, n = 4/12) [15,21,25,34]	32.9% (95% Cl: 28.1– 38.3%) (Fig 6)	33.8% (95%Cl: 27.5– 40.8%) (Fig 7)	31.5% (95% Cl: 24.8– 39.4%) (Fig 8)	From 15.7% (n = 57/362) [35] to 59% (n = 117/143) [29]	RLC/HIC: 0.93 RLC/ AIS:0.95
Ever or currently married MSM	7 [15,17,21,30,31,34]	6 (85.7%, n = 1/7) [15,17,21,31,32,34]	1 (14.3%, n = 1/7) [ <u>30]</u>	16.7% (95% Cl: 14.5– 19.4%) (Fig 9)	NA	NA	From (8.1%, n = 16/178) [21] to (21.5%, n = 43/200) [31]	NA
HIV positive men	21[15,16,21,24,29-45]	14 (66.7%, n = 14/21), [16,24,30,35–45]	7 (33.3%, n = 7/21) [15,21,29,31–34]	3.8% (95% CI: 2–5.7%) (Fig 10)	2.9% (95% Cl: 2–5%) (Fig 11)	6.5% (95% Cl: 3.8%- 12.3%) (Fig 12)	From 0.5% (n = 2/384)[33] to 23% (n = 46/200) [29]	RLC/ HIC:2.24 RLC/ AIS:1.71

#### Table 3. The proportion of first-time testers, non-recent testers, married MSM, and HIV-positive MSM.

AIS: for all included studies; HIC: High-income countries: RLC: Resource-limited countries; NA: not available. RLC/AIS: The proportion in resource-limited countries/the proportion for all included studies. RLC/HIC: The proportion in resource-limited countries/the proportion in high-income countries

https://doi.org/10.1371/journal.pone.0188890.t003

				Odds Ratio	Odd	s Ratio	
Study or Subgroup	log[Odds Ratio]	SE	Weight	IV, Random, 95% C	IV, Rand	om, 95% Cl	
Flowers2017	-1.70238	0.08762	8.5%	0.18 [0.15, 0.22]	•		
Greacen 2012	-1.97408	0.33747	8.0%	0.14 [0.07, 0.27]			
Grov2016	-2.78958	0.13084	8.5%	0.06 [0.05, 0.08]	-		
Han 2014	0.18417	0.07123	8.5%	1.20 [1.05, 1.38]		•	
Huang 2016	-2.1264	0.29342	8.1%	0.12 [0.07, 0.21]			
McDaid2016	-2.24854	0.06933	8.5%	0.11 [0.09, 0.12]	•		
Qin 2017	0.34956	0.10996	8.5%	1.42 [1.14, 1.76]		-	
Rosengren2016	-2.3383	0.31572	8.1%	0.10 [0.05, 0.18]			
Tao 2014	0.03637	0.13486	8.5%	1.04 [0.80, 1.35]		+	
Volk 2016	-1.69332	0.27202	8.2%	0.18 [0.11, 0.31]			
Yan 2015	-2.5416	0.32844	8.0%	0.08 [0.04, 0.15]			
Zhong 2016	-0.95551	0.15867	8.4%	0.38 [0.28, 0.52]	-		
Total (95% CI)			100.0%	0.23 [0.11, 0.48]	•		
Heterogeneity: Tau <sup>2</sup> =	1.61; Chi² = 1116.4	8, df = 11	(P < 0.000	001); I² = 99%			4000
Test for overall effect:	Z = 3.95 (P < 0.000	1)			U.UUT U.T	Eavours [control]	1000
						ravous icontion	

Fig 3. Meta-analysis of the proportion of first-time testers among MSM ever taking HIVST. Without comparison, this figure just presented OR value of pooled single proportion.

https://doi.org/10.1371/journal.pone.0188890.g003

Study or Subaroup	log[Odds Ratio] S	E Weight	Odds Ratio IV, Random, 95% Cl	Odd IV. Rand	s Ratio om, 95% Cl	
Grov2016	-2.78958 0.1308	4 19.2%	0.06 [0.05, 0.08]	-		
Rosengren2016	-2.3383 0.3157	2 13.4%	0.10 [0.05, 0.18]			
McDaid2016	-2.24854 0.0693	3 20.5%	0.11 [0.09, 0.12]			
Huang 2016	-2.1264 0.2934	2 14.1%	0.12 [0.07, 0.21]			
Greacen 2012	-1.97408 0.3374	7 12.7%	0.14 [0.07, 0.27]			
Flowers2017	-1.70238 0.0876	2 20.2%	0.18 [0.15, 0.22]	•		
Total (95% CI)		100.0%	0.11 [0.08, 0.16]	•		
Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	0.17; Chi² = 52.65, df = 5 (l Z = 11.57 (P < 0.00001)	P < 0.00001	); l² = 91%	0.01 0.1 Favours [experimental]	1 10 Favours [control]	100

Fig 4. Meta-analysis of the proportion of first-time testers in high-income countries. Without comparison, this figure just presented OR value of pooled single proportion.





percentage of non-recent testers was 32.9% (95% CI: 28.1–38.3%) (Fig 6) overall, 33.8% (95% CI: 27.5–40.8%) in high-income countries (Fig 7), and 31.5% (95% CI: 24.8–39.4%) in resource-constrained country settings (Fig 8).

The pooled percentage of ever or currently married MSM was 16.7% (95% CI: 14.5–19.4%) (Fig 9). The lowest and highest rates of ever or currently married MSM were (8.1%, n = 16/ 178) [21] in Guangzhou province of China and (21.5%, n = 43/200) [31] in Yunnan province of China, respectively.

The proportion of HIV positive individuals varied across studies, with the lowest proportion of 0.5% (n = 2/384) in Beijing [33] and the highest proportion of 23% (n = 46/200) in Yunnan, China [29]. The pooled proportion was 3.8% (95% CI: 2–5.7%) (Fig 10). The pooled proportion of HIV positive individuals was 2.9% (95% CI: 2–5%) in high-income countries (Fig 11), and 6.5% (95% CI: 3.8%-12.3%) (Fig 12) in resource-constrained countries(1.71 times higher than the total pooled proportion and 2.24 times than in the high-income countries).

#### Linkage-to-care rate

Fourteen studies evaluated the linkage-to-care rate for HIV-positive individuals [16,21,29,30,32-40,43]. Eight studies were conducted in high-income countries [16,35-40,43], while six [21,29,30,32-34] were in resource-limited countries. HIV-positive individuals were all linked to care in nine studies [16,21,30,32,34-36,40,43]. In the remaining five

				Odds Ratio	Odds Ratio	
Study or Subgroup	log[Odds Ratio]	SE	Weight	IV, Random, 95% CI	IV, Random, 95% Cl	
Greacen 2012	0	0.22086	7.6%	1.00 [0.65, 1.54]		
Grov 2016	-0.4697	0.06281	10.0%	0.63 [0.55, 0.71]	-	
Han 2014	-0.81229	0.07677	9.9%	0.44 [0.38, 0.52]	-	
Huang 2016	-0.46734	0.18603	8.2%	0.63 [0.44, 0.90]		
Jamil 2017	-1.67726	0.1443	8.9%	0.19 [0.14, 0.25]		
Marlin 2014	-0.8473	0.30861	6.1%	0.43 [0.23, 0.78]		
McDaid 2016	-0.34117	0.04134	10.2%	0.71 [0.66, 0.77]	•	
Qin 2017	-1.32493	0.1736	8.4%	0.27 [0.19, 0.37]		
Rosengren 2016	-0.50656	0.18465	8.2%	0.60 [0.42, 0.87]		
Volk 2016	-0.21441	0.1982	8.0%	0.81 [0.55, 1.19]		
Woods 2016	-1.33977	0.3387	5.6%	0.26 [0.13, 0.51]		
Zhong 2016	-0.71596	0.15134	8.8%	0.49 [0.36, 0.66]	-	
Total (95% CI)			100.0%	0.49 [0.39, 0.62]	◆	
Heterogeneity: Tau <sup>2</sup> =	0.14; Chi² = 136.19	, df = 11 (	P < 0.000	01); l² = 92%		+
Test for overall effect:	Z = 5.96 (P < 0.000	01)			U.U1 U.1 1 10	100
					Favours [experimental] Favours [control]	

Fig 6. Meta-analysis of the proportion of non-recent testers among MSM. Without comparison, this figure just presented OR value of pooled single proportion.

				Odds Ratio	Odds Rati	D	
Study or Subgroup	log[Odds Ratio]	SE	Weight	IV, Random, 95% Cl	IV, Random, 9	5% CI	
Greacen 2012	0	0.22086	11.8%	1.00 [0.65, 1.54]	_ <b>+</b> _		
Grov 2016	-0.4697	0.06281	15.2%	0.63 [0.55, 0.71]	•		
Huang 2016	-0.46734	0.18603	12.7%	0.63 [0.44, 0.90]			
Jamil 2017	-1.67726	0.1443	13.7%	0.19 [0.14, 0.25]			
Marlin 2014	-0.8473	0.30861	9.6%	0.43 [0.23, 0.78]	<b>_</b>		
McDaid 2016	-0.34117	0.04134	15.4%	0.71 [0.66, 0.77]	•		
Rosengren 2016	-0.50656	0.18465	12.7%	0.60 [0.42, 0.87]			
Woods 2016	-1.33977	0.3387	8.9%	0.26 [0.13, 0.51]			
Total (95% CI)			100.0%	0.51 [0.38, 0.69]	•		
Heterogeneity: Tau <sup>2</sup> =	0.15; Chi <sup>2</sup> = 92.15,	df = 7 (P <	< 0.00001)	); l <sup>2</sup> = 92%			
Test for overall effect:	7 = 4.42 (P < 0.000)	01)			0.01 0.1 1	10	100
	(1 - 0.000	0.1			Favours [experimental] Favo	ours [control]	







https://doi.org/10.1371/journal.pone.0188890.g008

studies, the percentages of linkage to care varied, with 31.3% (n = 5/16) [33] and 77.5% (n = 31/40) in China [29], 66.7% (n = 2/3) in France [37], 80% (n = 4/5) in the USA [39], 88% (n = 82/93) in the United Kingdom[38].

#### Discussion

Although HIVST was first introduced by Joint United Nations Programs on HIV/AIDS in 2000, it has not been widely implemented globally [46]. One of the main reasons is due to the lack of scientific evidences on the effectiveness of HIVST to promote HIV testing program. Potential harms of HIVST without supervision and disengagement in HIV care for self-testers

				Odds Ratio		Odds	s Ratio	
Study or Subgroup	log[Odds Ratio]	SE	Weight	IV, Random, 95% Cl		IV, Rande	om, 95% Cl	
Han 2014	-1.70739	0.07573	23.1%	0.18 [0.16, 0.21]				
Li 2016	-1.29505	0.17212	14.4%	0.27 [0.20, 0.38]				
Qin 2017	-1.5107	0.10215	20.6%	0.22 [0.18, 0.27]		-		
Tao2014	-1.38629	0.17678	14.0%	0.25 [0.18, 0.35]				
Volk 2016	-1.76929	0.27934	8.2%	0.17 [0.10, 0.29]				
Yan 2015	-1.54933	0.22476	10.8%	0.21 [0.14, 0.33]				
Zhong 2016	-2.31501	0.26206	8.9%	0.10 [0.06, 0.17]				
Total (95% CI)			100.0%	0.20 [0.17, 0.24]		•		
Heterogeneity: Tau <sup>2</sup> =	0.03; Chi <sup>2</sup> = 15.18,	df = 6 (P =	= 0.02); l <sup>2</sup>	= 60%			1 10	100
Test for overall effect:	Z = 16.81 (P < 0.00	001)			Favo	ours [experimental]	Favours [control]	100

Fig 9. Meta-analysis of the proportion of ever or currently married MSM. Without comparison, this figure just presented OR value of pooled single proportion.

				Odds Ratio	Odds Ratio
Study or Subgroup	log[Odds Ratio]	SE	Weight	IV, Random, 95% C	CI IV, Random, 95% CI
Carballo-Die´guez 2012	-2.61496	0.5981	4.3%	0.07 [0.02, 0.24]	·
Chavez 2016	-3.81671	0.3048	5.4%	0.02 [0.01, 0.04]	·
Daniels2016	-3.58352	1.01379	2.9%	0.03 [0.00, 0.20]	
Elliot 2017	-4.0985	0.10455	5.8%	0.02 [0.01, 0.02]	-
Flowers2017	-2.88306	0.13157	5.8%	0.06 [0.04, 0.07]	-
Greacen2012	-3.51155	0.71758	3.8%	0.03 [0.01, 0.12]	
Grov 2016	-4.73859	0.30283	5.4%	0.01 [0.00, 0.02]	<b>⊢←</b>
Grov2016	-4.73859	0.30283	5.4%	0.01 [0.00, 0.02]	←
Han 2014	-2.73622	0.07573	5.8%	0.06 [0.06, 0.08]	
Huang 2016	-4.09434	0.71297	3.9%	0.02 [0.00, 0.07]	· ←
Jamil 2017	-4.06617	0.58228	4.4%	0.02 [0.01, 0.05]	<b>↓ ←</b>
Li 2016	-1.20831	0.16803	5.7%	0.30 [0.21, 0.42]	
Marlin 2014	-2.75154	0.59549	4.3%	0.06 [0.02, 0.21]	
McDaid2016	-3.23809	0.08807		Not estimable	
Qin2017	-2.01823	0.16829	5.7%	0.13 [0.10, 0.18]	
Rosengren2016	-3.29584	0.72008	3.8%	0.04 [0.01, 0.15]	
Tao2014	-1.7346	0.18881	5.7%	0.18 [0.12, 0.26]	
Volk2016	-3.92197	0.71407	3.9%	0.02 [0.00, 0.08]	<b>↓ ←</b>
Wong 2015	-3.07577	0.59052	4.3%	0.05 [0.01, 0.15]	·
Woods 2016	-2.26176	0.46993	4.8%	0.10 [0.04, 0.26]	
Zhong2016	-3.05636	0.36178	5.2%	0.05 [0.02, 0.10]	
Zhou2015	-5.25227	0.70896	3.9%	0.01 [0.00, 0.02]	←
Total (95% CI)			100.0%	0.04 [0.02. 0.06]	◆
Heterogeneity: $Tau^2 = 0.9$	$3^{\circ}$ Chi <sup>2</sup> = 408 81 df	· · · · · · · · · · · · · · · · · · ·			
Test for overall effect: 7 =	13.51 (P < 0.000)	0.01 0.1 1 10 100			
	10.01 (1 - 0.0000	''		I	Favours [experimental] Favours [control]

Fig 10. Meta-analysis of the proportion of HIV-positive men among MSM. Without comparison, this figure just presented OR value of pooled single proportion.

				Odds Ratio	Odds Ratio			
Study or Subgroup	log[Odds Ratio]	SE	Weight	IV, Random, 95% CI	IV, I	<u>Random, 95%</u>	6 CI	
Carballo-Die´guez 2012	-2.61496	0.5981	5.8%	0.07 [0.02, 0.24]				
Chavez 2016	-3.81671	0.3048	9.2%	0.02 [0.01, 0.04]				
Daniels2016	-3.58352	1.01379	3.0%	0.03 [0.00, 0.20]	← • • • • • • • • • • • • • • • • • • •			
Elliot 2017	-4.0985	0.10455	11.3%	0.02 [0.01, 0.02]				
Flowers2017	-2.88306	0.13157	11.1%	0.06 [0.04, 0.07]	-			
Greacen2012	-3.51155	0.71758	4.7%	0.03 [0.01, 0.12]	<b>←</b>			
Grov2016	-4.73859	0.30283	9.3%	0.01 [0.00, 0.02]	←			
Huang 2016	-4.09434	0.71297	4.7%	0.02 [0.00, 0.07]	<b>.</b>			
Jamil 2017	-4.06617	0.58228	5.9%	0.02 [0.01, 0.05]	←			
Marlin 2014	-2.75154	0.59549	5.8%	0.06 [0.02, 0.21]				
McDaid2016	-3.23809	0.08807	11.4%	0.04 [0.03, 0.05]	-			
Rosengren2016	-3.29584	0.72008	4.7%	0.04 [0.01, 0.15]	← -			
Wong 2015	-3.07577	0.59052	5.8%	0.05 [0.01, 0.15]				
Woods 2016	-2.26176	0.46993	7.2%	0.10 [0.04, 0.26]				
			400.0%	0.02 [0.02.0.05]				
	<b>▼</b>							
Heterogeneity: Tau <sup>2</sup> = 0.3	0.01 0.1	1	10	100				
l est for overall effect: $Z =$	avours [experime	ental] Favou	rs [contro	ol]				

Fig 11. Meta-analysis of the proportion of HIV-positive men in high-income countries. Without comparison, this figure just presented OR value of pooled single proportion.

				Odds Ratio	Odds Ratio			
Study or Subgroup	log[Odds Ratio]	SE	Weight	IV, Random, 95% CI		IV, Random, 95% Cl		
Han 2014	-2.73622	0.07573	17.1%	0.06 [0.06, 0.08]				
Li 2016	-1.20831	0.16803	16.5%	0.30 [0.21, 0.42]				
Qin2017	-2.01823	0.16829	16.5%	0.13 [0.10, 0.18]		-		
Tao2014	-1.7346	0.18881	16.3%	0.18 [0.12, 0.26]	-	-		
Volk2016	-3.92197	0.71407	9.6%	0.02 [0.00, 0.08]	←			
Zhong2016	-3.05636	0.36178	14.3%	0.05 [0.02, 0.10]				
Zhou2015	-5.25227	0.70896	9.6%	0.01 [0.00, 0.02]	←			
Total (95% CI)			100.0%	0.07 [0.04, 0.14]	•			
Heterogeneity: Tau <sup>2</sup> = 0.64; Chi <sup>2</sup> = 111.58, df = 6 (P < 0.00001); l <sup>2</sup> = 95%							1 10	100
Test for overall effect: Z = 7.86 (P < 0.00001)					Favours [exp	erimental]	Favours [control]	100



with positive results exacerbate the concerns [21]. The 23 articles/abstracts we retrieved in this meta-analysis were all published in the last 5 years. Few studies globally produced rigorous evidence on evaluation of HIVST to improve HIV testing for MSM, with only two RCT-based studies. Most of the studies were carried out in United States of America (10 studies) and China (8 studies), possibly because we restricted the languish only to English and Chinese. However, China is currently on its way to enlarge HIV testing program by integrating HIVST approach, which is illustrated by China's "The 13th Five-year" plan on HIV/AIDS prevention and control (2017), which put an emphasis on promoting HIVST among MSM and their sexual partners[47].

Globally, HIV test frequency is low among MSM, especially in resource limited countries. The average number of site-based HIV testing was 0.47 test every 6 months for MSM in Australia[48], while in China, the average number of lifetime HIV tests was only 1–2 [6].Our meta-analysis showed that HIVST could improve HIV test frequency for MSM by one more test every 6 months, which has the substantial potential to assist the traditional HIV testing service to meet the guideline recommendation that MSM with high risk behaviors (unprotected anal sex, multiple sex partners, use of recreational drugs, etc.) need a HIV test every 3–6 months[49,50].As a supplementary testing service, HIVST could especially increase the test frequency 3.95 times for those delayed testers, who usually complained of the long distance transportation to the site-based services, long waiting time for the results, and the risk of being stigmatized by people working in the site-based service center[51].

Oral-fluid based HIVST kits have been approved by authority in the U.S.A.,U.K and France [35]. However, it has not received approval from the regulators in Hong Kong, China, Australia and Brazil[35]. Oral-fluid kits are less painful but more expensive than finger-prick kits which might be more acceptable in resource limited countries. In our meta-analysis, there were RCTs to explore the effectiveness of the oral-fluid kits to improve HIV testing frequency, but none were using finger-prick kits. Thus, more RCT studies in different cultural and economic settings are needed to provide more evidence for the efficacy of finger-prick kits to increase HIV testing frequency.

Having the non-testers and delayed testers of MSM get HIV tests is the main goal of expanding HIV testing among the high risk population. But is the HIVST superior than sitebased testing services to reach those high risk population? Based on the current evidence, 18.7% of HIV self testers were first time testers, and 32.9% were non-recent testers, similar with the proportion of site-based HIV testing services among these two outcomes, 11.9%-34.9% for the first time testers among MSM [52,53] and 26.6%-33.3% for the non-recent testers test [54–56]. Thus, HIVST has equivalent potential with site-based HIV testing to reach those at high risk who are not accessing traditional HIV testing services. However, the capacity of HIVST to reach that high-risk population is different depending on the social economic status in the study settings. Our meta-analysis showed that HIVST could reach 3.32 times more first time testers in resource-limited countries (32.9%) than in high-income countries (9.9%). The rationale is that free providing of HIVST kits during the studies became an incentive for economically vulnerable MSM. This is a significant evidence implying that free or low cost of HIVST services could be much more effective to enlarge HIV testing in resource limited countries than high income countries. Because the cost of the self-testing kits has been proved to be a big barrier for people to use it [21,57,58]. Thus, social economic status is an important factor when implementing HIVST services.

Unlike western developed countries, a significant proportion of MSM in developing countries married or would marry with female, for example, currently 17.0% (95% CI: 15.1%– 19.1%) of MSM were married with women in China[59], and 30%-40% of MSM were married with women in India[60,61]. With comparable HIV burdens to unmarried MSM [62], only 7.1% of HIV positive married MSM ever took HIV testing last year [62]. Married MSM were assumed to have more barriers to having an HIV test [63]. However, no summarized evidence showed the effectiveness of HIVST to reach this hidden subgroup of men. Our meta-analysis showed married MSM accounted for 16.7% of MSM who had ever taken HIVST. This was a comparable proportion to that of MSM who had taken a site-based HIV test (around 16%-17%) [44, 47]. Therefore, HIVST doesn't have a superior capacity to reach the hidden population of married MSM. Recommendation for future research may include qualitative study to examine barriers and facilitators of the implementation of HIVST for married MSM. Besides, HIVST could be provided as a complementary testing approach to site-based testing services, in order to better reach this hidden population, and prevent HIV transmission from MSM to their female partners.

According to Global AIDS Response Progress Reporting data from 96 countries, the median HIV prevalence among MSM is 3.7% [64]. The proportion of HIV positive MSM in China was 6%-8% reported by UNAIDS [50].Our meta-analysis results revealed the similar proportions (3.8% in total, 6.5% in resource-limited countries, and 2.9% in high-income countries). Thus, HIVST has a similar potential to reach individuals living with HIV compared with the site-based HIV testing approach. The current evidence also showed that HIVST did not reduce the linkage to care rate (most HIV-positive individuals were linked to care in the retrieved studies). However, there is still a gap to meet the 90-90-90 target goal. Strategies to facilitate the linkage to care for self-tested HIV positive MSM are needed to maximize the benefits of HIVST.

### Limitations

This meta-analysis has several limitations. First, the evidence included in the data synthesis on the efficacy of HIVST to improve HIV test frequency was not as strong as expected, since there were only two RCT-designed studies, and both were implemented in high-income countries. Lack of data from resource-limited countries constrains our ability to examine the efficacy of HIVST on improving the HIV test frequency in diverse country settings. Second, selection bias cannot be ruled out because languages were limited to English and Chinese. Third, information bias also likely exists, because some outcomes were evaluated by the participants' self-reporting. The risk of bias within the studies was assessed using Agency for Healthcare Research and Quality (AHRQ) methods, but some assessment items were not applicable due to the type of study design which limits our ability to make a graph for the risk of bias. Fourth, the heterogeneity across included studies was high in this meta-analysis. The main reasons

might be that the outcomes lacked standard definitions across the studies (such as the "non-recent testers") and samples were recruited from diverse settings.

#### **Conclusions and implications**

Our meta-analysis indicated that as a complementary approach for HIV site-based testing services, HIVST has potential to improve test frequency and has the equivalent capacity to reach the first-time, delayed, married and HIV-infected testers among MSM, and could effectively link HIV-infected MSM to medical care. Thus HIVST could potentially contribute to achieving WHO's 90-90-90 target goal, and specifically the first target of diagnosing 90% of all people with HIV. However, because of the limited studies on HIVST, we do not know which self-testing approach (oral-fluid based, or finger-prick based) is more acceptable and effective in term of improving HIV testing for MSM. More rigorous study designs are needed to explore the specific self testing approach on improving HIV testing for MSM in certain social economic settings.

#### Supporting information

**S1 Doc. JBI critical appraisal tools.** (DOCX)

**S1** Table. Assessment of methodological quality of randomized controlled trials(n = 2). (DOCX)

S2 Table. Assessment of methodological quality of cross sectional studies (n = 6). (DOCX)

**S3** Table. Assessment of methodological quality of quasi-experimental studies (n = 14). (DOCX)

**S4** Table. Risk of bias assessment within the studies (n = 23). (DOCX)

**S1 PRISMA Checklist.** (DOC)

#### **Acknowledgments**

This study is funded by Fogarty International Center Award (D43 TW009579) (https:// www.fic.nih.gov/Pages/Default.aspx), and partly funded by National Social Science Fund (15CSH037) (http://www.npopss-cn.gov.cn/). The authors have declared that no competing interests exist.

#### **Author Contributions**

Conceptualization: Ci Zhang, Xianhong Li. Funding acquisition: Xianhong Li. Methodology: Ci Zhang, Xianhong Li. Software: Ci Zhang, Mary-Lynn Brecht. Supervision: Xianhong Li, Deborah Koniak-Griffin. Validation: Ci Zhang, Xianhong Li, Mary-Lynn Brecht. Visualization: Ci Zhang, Xianhong Li, Mary-Lynn Brecht.

Writing - original draft: Ci Zhang, Xianhong Li.

Writing - review & editing: Xianhong Li, Mary-Lynn Brecht, Deborah Koniak-Griffin.

#### References

- 1. US Department of Health and Human Services. HIV/AIDS 101: global statistics. 2017 [cited 2017 May 2]. https://www.aids.gov/hiv-aids-basics/hivaids-101/global-statistics/index.html
- 2. World Health Organization. Global Health Observatory (GHO) data. 2017 [cited 2017 May 2]. http://www.who.int/gho/hiv/en/
- 3. UNAIDS. AIDS by the numbers: AIDS is not over, but it can be. 2016 [cited 2017 May 2]. http://www. unaids.org/en/resources/documents/2016/AIDS-by-the-numbers
- 4. The Henry J. Kaiser Family Foundation. The global HIV/AIDS epidemic. 2017 [cited 2017 May 2]. http:// kff.org/global-health-policy/fact-sheet/the-global-hivaids-epidemic/#footnote-UNAIDSGlobalReport
- 5. Ministry of Health of the People's Republic of China. 2012 China AIDS response progress report. 2012. http://www.unaids.org.cn/pics/20120614140133.pdf
- Zou H, Hu N, Xin Q, Beck J. HIV testing among men who have sex with men in China: a systematic review and meta-analysis. AIDS Behav. 2012; 16:1717–28. https://doi.org/10.1007/s10461-012-0225y PMID: 22677975
- Zou H, Wu Z, Yu J, Li M, Ablimit M, Li F, et al. Sexual risk behaviors and HIV infection among men who have sex with men who use the internet in Beijing and Urumqi, China. J Acquir Immune Defic Syndr. 2010; 53 Suppl 1:S81–7.
- Wang HY, Xu JJ, Zou HC, Reilly KH, Zhang CM, Yun K, et al. Sexual risk behaviors and HIV infection among men who have sex with men and women in China: evidence from a systematic review and metaanalysis. BioMed Res Int. 2015; 2015:850132. https://doi.org/10.1155/2015/850132 PMID: 26779538
- Valdiserri RO. Late HIV diagnosis: bad medicine and worse public health. PLoS Med. 2007; 4(6):e200. https://doi.org/10.1371/journal.pmed.0040200 PMID: 17564489
- UNAIDS. Fast-Track: Ending the AIDS epidemic by 2030. 2014 [cited 2017 May 2]. http://www.unaids. org/sites/default/files/media\_asset/JC2686\_WAD2014report\_en.pdf
- 11. World Health Organization. Guidelines on HIV self-testing and partner notification: supplement to consolidated guidelines on HIV testing services. 2016 [cited 2017 May 2]. http://www.who.int/hiv/pub/vct/ hivself-testing-guidelines/en/
- Pant Pai N, Sharma J, Shivkumar S, Pillay S, Vadnais C, Joseph L, et al. Supervised and unsupervised self-testing for HIV in high- and low-risk populations: a systematic review. PLoS Med. 2013; 10(4): e1001414. https://doi.org/10.1371/journal.pmed.1001414 PMID: 23565066
- Frye V, Wilton L, Hirshfied S, Chiasson MA, Usher D, Lucy D, et al. "Just because it's out there, people aren't going to use it." HIV self-testing among young, black MSM, and transgender women. AIDS Patient Care STDS. 2015; 29:617–24. https://doi.org/10.1089/apc.2015.0100 PMID: 26376029
- Bilardi JE, Walker S, Read T, Prestage G, Chen MY, Guy R, et al. Gay and bisexual men's views on rapid self-testing for HIV. AIDS Behav. 2013; 17:2093–9. https://doi.org/10.1007/s10461-012-0395-7 PMID: 23297083
- Han L, Bien CH, Wei C, Muessig KE, Yang M, Liu F, et al. HIV self-testing among online MSM in China: implications for expanding HIV testing among key populations. J Acquir Immune Defic Syndr. 2014; 67:216–21. https://doi.org/10.1097/QAI.00000000000278 PMID: 24991972
- Wong HT, Tam HY, Chan DP, Lee SS. Usage and acceptability of HIV self-testing in men who have sex with men in Hong Kong. AIDS Behav. 2015; 19:505–15. <u>https://doi.org/10.1007/s10461-014-0881-1</u> PMID: 25145608
- Yan H, Yang H, Raymond HF, Li J, Shi LE, Huan X, et al. Experiences and correlates of HIV self-testing among men who have sex with men in Jiangsu province, China. AIDS Behav. 2015; 19:485–91. <a href="https://doi.org/10.1007/s10461-014-0968-8">https://doi.org/10.1007/s10461-014-0968-8</a> PMID: 25480598
- Wei C, Yan H, Yang C, Raymond HF, Li J, Yang H, et al. Accessing HIV testing and treatment among men who have sex with men in China: a qualitative study. AIDS Care. 2014; 26:372–8. <u>https://doi.org/ 10.1080/09540121.2013.824538 PMID: 23909807</u>
- Spielberg F, Levine RO, Weaver M. Self-testing for HIV: a new option for HIV prevention? Lancet Infect Dis. 2004; 4:640–6. https://doi.org/10.1016/S1473-3099(04)01150-8 PMID: 15451493
- 20. Wright AA, Katz IT. Home testing for HIV. NEJM. 2006; 354:437–40. https://doi.org/10.1056/ NEJMp058302 PMID: 16452553

- **21.** Zhong F, Tang W, Cheng W, Lin P, Wu Q, Cai Y, et al. Acceptability and feasibility of a social entrepreneurship testing model to promote HIV self-testing and linkage to care among men who have sex with men. HIV Med. 2017; 18(5):376–82. https://doi.org/10.1111/hiv.12437 PMID: 27601301
- 22. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(6):e1000097.
- 23. The Joanna Briggs Institute. Joanna Briggs Institute reviewer's manual (2016 ed.). Australia: The Joanna Briggs Institute; 2016.
- 24. Flowers P, Riddell J, Park C, Ahmed B, Young I, Frankis J, et al. Preparedness for use of the rapid result HIV self-test by gay men and other men who have sex with men (MSM): a mixed methods exploratory study among MSM and those involved in HIV prevention and care. HIV Med. 2017; 18:245–55. <u>https:// doi.org/10.1111/hiv.12420 PMID: 27492141</u>
- Katz D, Golden M, Hughes J, Farquhar C, Stekler J. HIV self-testing increases HIV testing frequency among high-risk men who have sex with men: a randomized controlled trial. Presented at: 8th International AIDS Society Conference. 2015, July 19–22; Vancouver, Canada; 2015.
- 26. Viswanathan M, Ansari MT, Berkman ND, Chang S, Hartling L, McPheeters M, et al. AHRQ methods for effective health care: assessing the risk of bias of individual studies in systematic reviews of health care interventions. In: Agency for Healthcare Research and Quality. Methods guide for effectiveness and comparative effectiveness reviews. Rockville, Maryland (USA): Agency for Healthcare Research and Quality; 2008: 14.
- Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ. 1997; 315(7109):640–5. PMID: 9310565
- Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ. 2006; 333(7568):597–600. https://doi.org/10.1136/bmj.333.7568.597 PMID: 16974018
- Qin Y, Tang W, Nowacki A, Mollan K, Reifeis SA, Hudgens MG, et al. Benefits and potential harms of human immunodeficiency virus self-testing among men who have sex with men in China: an implementation perspective. STDS. 2017; 44(4):233–8.
- Huang E, Marlin RW, Young SD, Medline A, Klausner JD. Using Grindr, a smartphone social-networking application, to increase HIV self-testing among Black and Latino men who have sex with men in Los Angeles, 2014. AIDS Educ Prev 2016; 28(4):341–50. <u>https://doi.org/10.1521/aeap.2016.28.4.341</u>
   PMID: 27427928
- 31. Li Y, Wang Y, Zhang R, Wang J, Li Z, Wang L, et al. [Analysis on accuracy and influencing factors of oral fluid based rapid HIV self-testing among men who have sex with men]. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2016; 37(1):72–5. <u>https://doi.org/10.3760/cma.j.issn.0254-6450.2016.01.015 PMID: 26822647</u>
- **32.** Tao J, Li MY, Qian HZ, Wang LJ, Zhang Z, Ding HF, et al. Home-based HIV testing for men who have sex with men in China: a novel community-based partnership to complement government programs. PloS One. 2014; 9(7):e102812. https://doi.org/10.1371/journal.pone.0102812 PMID: 25051160
- 33. Zhou YH. Infection and factors of HIV and syphilis and regular sexual partner interference among men who have sex with men in Beijing. Sooghow University. 2015. http://kns.cnki.net/KCMS/detail/detail. aspx?dbcode=CMFD&dbname=CMFD201601&filename=1015405888.nh&v=MDg2MDIxTHV4W VM3RGgxVDNxVHJXTTFGckNVUkwyZII1Um1GeXpuVmJ6S1ZGMjZHN2U0RzluRXA1RWJQ SVI4ZVg=
- Volk JE, Lippman SA, Grinsztejn B, Lama JR, Fernandes NM, Gonzales P, et al. Acceptability and feasibility of HIV self-testing among men who have sex with men in Peru and Brazil. Int J STD AIDS. 2016; 27(7):531–6. https://doi.org/10.1177/0956462415586676 PMID: 25971262
- Jamil MS, Prestage G, Fairley CK, Grulich AE, Smith KS, Chen M, et al. Effect of availability of HIV selftesting on HIV testing frequency in gay and bisexual men at high risk of infection (FORTH): a waiting-list randomised controlled trial. Lancet HIV. 2017 Jun; 4(6):e241–e250. https://doi.org/10.1016/S2352-3018(17)30023-1 PMID: 28219619
- Marlin RW, Young SD, Bristow CC, Wilson G, Rodriguez J, Ortiz J, et al. Piloting an HIV self-test kit voucher program to raise serostatus awareness of high-risk African Americans, Los Angeles. BMC Public Health. 2014; 14:1226. https://doi.org/10.1186/1471-2458-14-1226 PMID: 25427749
- Greacen T, Friboulet D, Fugon L, Hefez S, Lorente N, Spire B. Access to and use of unauthorised online HIV self-tests by internet-using French-speaking men who have sex with men. Sex Transm Infect. 2012; 88(5):368–74. https://doi.org/10.1136/sextrans-2011-050405 PMID: 22436195
- Elliot E, Rossi M, McCormack S, McOwan A. Identifying undiagnosed HIV in men who have sex with men (MSM) by offering HIV home sampling via online gay social media: a service evaluation. Sex Transm Infect. 2016; 92(6):470–3. https://doi.org/10.1136/sextrans-2015-052090 PMID: 27221475
- Woods WJ, Lippman SA, Agnew E, Carroll S, Binson D. Bathhouse distribution of HIV self-testing kits reaches diverse, high-risk population. AIDS Care. 2016; 28 Suppl 1:111–3.

- 40. Grov C, Cain D, Whitfield TH, Rendina HJ, Pawson M, Ventuneac A, et al. Recruiting a U.S. national sample of HIV-negative gay and bisexual men to complete at-home self-administered HIV/STI testing and surveys: Challenges and opportunities. Sex Res Social Policy. 2016; 13(1):1–21. https://doi.org/ 10.1007/s13178-015-0212-y PMID: 26858776
- McDaid LM, Aghaizu A, Frankis J, Riddell J, Nardone A, Mercey D, et al. Frequency of HIV testing among gay and bisexual men in the UK: implications for HIV prevention. HIV Med. 2016; 17(9):683–93. https://doi.org/10.1111/hiv.12373 PMID: 26991460
- Daniels J, Rosengren L, Young S, Klausner JD. Will men who have sex with men use short-messaging services to send photos of completed HIV self-tests to researchers? JANAC. 2016; 27(5):722–6. https://doi.org/10.1016/j.jana.2016.05.002 PMID: 27293208
- Rosengren AL, Huang E, Daniels J, Young SD, Marlin RW, Klausner JD. Feasibility of using GrindrTM to distribute HIV self-test kits to men who have sex with men in Los Angeles, California. Sex Health. 2016. https://doi.org/10.1071/SH15236 PMID: 27209076
- 44. Carballo-Dieguez A, Frasca T, Balan I, Ibitoye M, Dolezal C. Use of a rapid HIV home test prevents HIV exposure in a high risk sample of men who have sex with men. AIDS Behav. 2012; 16(7):1753–60. https://doi.org/10.1007/s10461-012-0274-2 PMID: 22893194
- Chavez P. R, Wesolowski L. D, Owen S. M, Gravens L, Sullivan P, Macgowan R J. Perceptions and Performance of Self-Administered Rapid HIV Tests Conducted by Untrained Users in Real World Settings. HIV Diagnostics Conference. 2016, May 21–24; Atlanta, USA; 2016.
- Campbell S, Klein R. Home testing to detect human immunodeficiency virus: boon or bane? J Clin Microbiol 2006; 44:3473–6. https://doi.org/10.1128/JCM.01511-06 PMID: 17021069
- 47. State Council. The "13th Five-year Plan" on HIV prevention and control in China. 2017[cited 2017 May 2]. http://www.gov.cn/zhengce/content/2017-02/05/content\_5165514.htm
- Read TR, Hocking JS, Bradshaw CS, Morrow A, Grulich AE, Fairley CK, et al. Provision of rapid HIV tests within a health service and frequency of HIV testing among men who have sex with men: randomised controlled trial. Br Med J (Clin Res Ed). 2013; 347:f5086.
- 49. Patel RR, Patel S, Clarke E, Khan AW, Doshi B, Radcliffe KW. Guidance and practice on frequency of HIV and sexually transmitted infection testing in men who have sex with men—what is the European situation? Int J STD AIDS. 2014; 25(3):213–8. <u>https://doi.org/10.1177/0956462413497700</u> PMID: 24216033
- Templeton DJ, Read P, Varma R, Bourne C. Australian sexually transmissible infection and HIV testing guidelines for asymptomatic men who have sex with men 2014: a review of the evidence. Sex Health. 2014; 11(3):217–29. https://doi.org/10.1071/SH14003 PMID: 24690473
- UNAIDS. The gap report [EB/OL]; 2015 [cited 2017 May 2]. <u>http://www.unaids.org/sites/default/files/</u> media\_asset/UNAIDS\_Gap\_report\_en.pdf
- Bai X, Xu J, Yang J, Yang B, Yu M, Gao Y, et al. HIV prevalence and high-risk sexual behaviours among MSM repeat and first-time testers in China: implications for HIV prevention. J Int AIDS Soc. 2014; 17:18848. https://doi.org/10.7448/IAS.17.1.18848 PMID: 24993457
- 53. Mdodo R, Thomas PE, Walker A, Chavez P, Ethridge S, Oraka E, et al. Rapid HIV testing at gay pride events to reach previously untested MSM: U.S., 2009–2010. Public Health Rep. 2014; 129:328–34. https://doi.org/10.1177/003335491412900407 PMID: 24982535
- 54. Marcus U, Gassowski M, Drewes J. HIV risk perception and testing behaviours among men having sex with men (MSM) reporting potential transmission risks in the previous 12 months from a large online sample of MSM living in Germany. BMC Public Health. 2016; 16(1):1111. <u>https://doi.org/10.1186/s12889-016-3759-5 PMID: 27770775</u>
- 55. EMIS 2010: The European Men-Who-Have-Sex-With-Men Internet Survey. Findings from 38 countries: The EMIS Network; 2010 [cited 2017 May 2]. http://ecdc.europa.eu/en/publications/Publications/EMIS-2010-european-men-who-have-sex-with-men-survey.pdf
- 56. Marcus U, Gassowski M, Kruspe M, Drewes J. Recency and frequency of HIV testing among men who have sex with men in Germany and socio-demographic factors associated with testing behaviour. BMC Public Health. 2015; 15. https://doi.org/10.1186/s12889-015-1945-5 PMID: 26223447
- Figueroa C, Johnson C, Verster A, Baggaley R. Attitudes and Acceptability on HIV Self-testing Among Key Populations: A Literature Review. AIDS Behav. 2015; 19(11):1949–65. <u>https://doi.org/10.1007/</u> s10461-015-1097-8 PMID: 26054390
- Marley G, Kang D, Wilson EC, Huang T, Qian Y, Li X, et al. Introducing rapid oral-fluid HIV testing among high risk populations in Shandong, China: feasibility and challenges. BMC public health. 2014; 14:422. https://doi.org/10.1186/1471-2458-14-422 PMID: 24884431

- 59. Chow Eric P F, Wilson D P, Zhang L. What is the potential for bisexual men in China to act as a bridge of HIV transmission to the female population? Behavioural evidence from a systematic review and meta-analysis. BMC Infectious Diseases. 2011; 11(1):1–17.
- 60. Go V F, Srikrishnan A K, Sivaram S, Murugavel G K, Galai N, Johnson S C, et al. High HIV prevalence and risk behaviors in men who have sex with men in Chennai, India. Journal of Acquired Immune Deficiency Syndromes. 2004; 35(3):314–319. PMID: 15076248
- Solomon S S, Srikrishnan A K, Sifakis F, Mehta S H, Vasudevan C K, Balakrishnan P, et al. The emerging HIV epidemic among men who have sex with men in Tamil Nadu, India: geographic diffusion and bisexual concurrency. AIDS Behav, 2010; 14(5):1001–1010. <u>https://doi.org/10.1007/s10461-010-</u> 9711-2 PMID: 20467890
- Mayer KH, Gangakhedkar R, Sivasubramanian M, Biello KB, Abuelezam N, Mane S, et al. Differing Identities but Comparably High HIV and Bacterial Sexually Transmitted Disease Burdens Among Married and Unmarried Men Who Have Sex With Men in Mumbai, India. Sex Transm Dis.2015; 42(11):629– 33. https://doi.org/10.1097/OLQ.0000000000344 PMID: 26462187
- 63. Li J, Yu A, Yang C, Wang B, Yang M, Meng L.Situation and correlated behavior of HIV infection among currently married MSM in Gansu province. Zhonghua Liu Xing Bing Xue Za Zhi. 2014; 35(7): 809–11. PMID: 25294072
- 64. UNAIDS. 2014 Progress reports submitted by countries: 2014 [cited 2017 May 2]. http://www.unaids. org/en/dataanalysis/knowyourresponse/countryprogressreports/2014countries